Landmark Clinical Data Shows Deep Reduction in Disease-Causing Protein After Single Infusion of NTLA-2001, an Investigational CRISPR/Cas9 Therapy for Transthyretin (ATTR) Amyloidosis; First-Ever Clinical Data Supporting in Vivo CRISPR Genome Editing in Humans

On June 26, 2021, Intellia Therapeutics, Inc. (NASDAQ: NTLA) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced positive interim data from an ongoing Phase 1 clinical study of their lead in vivo genome editing candidate, NTLA-2001, which is being developed as a single-dose treatment for transthyretin (ATTR) amyloidosis. The Phase 1 study, run by Intellia as the program's development and commercialization lead, is evaluating NTLA-2001 in people living with hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN). NTLA-2001 is the first CRISPR/Cas9-based therapy candidate to be administered systemically, via intravenous infusion, for precision editing of a gene in a target tissue in humans. NTLA-2001 is designed to inactivate the TTR gene in liver cells to prevent the production of misfolded transthyretin (TTR) protein, which accumulates in tissues throughout the body and causes the debilitating and often fatal complications of ATTR amyloidosis. The interim data were presented on June 26, 2021 at the 2021 Peripheral Nerve Society (PNS) Annual Meeting and published online on June 26, 2021 in The New England Journal of Medicine.

Login Or Register To Read Full Story